Navigation Links
Regenicin, Inc., RGIN - Update

LITTLE FALLS, N.J., Feb. 2, 2011 /PRNewswire/ -- Regenicin, Inc.(OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs announced today that its Chairman and CEO, Randall McCoy is currently working with the board on a new Corporate incentive plan designed to encourage and reward the Company's officers, employees and consultants working with Regenicin.  As a show of his own commitment to the Company's growth and stability, Mr. McCoy has pledged to return 22 million of his own personal shares back into Treasury to support the program -- over 26% of the currently issued and outstanding shares of Regenicin."  

"I really believe in the future success of this Company and want all the people who are making it happen to benefit with me," said Mr. McCoy regarding the new incentive program.  "The best way I know how to do that without diluting the existing shareholders is to contribute my own shares to the program.  While this will reduce my holdings by nearly half, I believe it will enhance the overall value of the company creating a win, win for all the shareholders."

When asked about the recent adverse market activity, Mr. McCoy commented that it seemed particularly odd in view of the fact that the Company had incurred no fundamental change or negative developments. "The company remains on track and committed to its original business plan and creating value for the company and its shareholders."

About Regenicin

Regenicin, Inc. ( is a development stage biotechnology company. Regenicin is a publicly traded company, with headquarters in New Jersey. Additional information can be found in the company's filings with the Securities and Exchange Commission located at

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Regenicin, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioCells, Inc., a Cord Blood America Company, to Begin Storing Dental Pulp Stem Cells in Argentina
2. ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial
3. Johnson & Johnson Consumer Companies, Inc., Unveils CYTOMIMIC(TM) Technology at 68th Annual Meeting of the American Academy of Dermatology
4. LS9, Inc., U.C Berkeley, and JBEI Make Major Breakthrough in Cellulosic Fuels Production
5. BioSpec Global Solutions Inc., contracts with RMF Design & Manufacturing Inc., for production of the TOGs 3000 and 9000 units for U.S. market
6. Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology
7. ValGenesis, Inc., the Leading Provider of Validation Lifecycle Management Solutions to Regulated Life Science Companies, Today Announced Support for EMC Documentum v.6.5
8. BioStorage Technologies, Inc., Welcomes Catherine Michael as Global Head of Sample Management Operations
9. Sigma-Aldrich Acquires ChemNavigator, Inc., to Provide Researchers With Industry-Leading Chemical Compound Selection and Procurement Services
10. avVaa World Health Care Products, Inc. Signs Agreement with 3PL Worldwide, Inc., for Order Management & Fulfillment for avVaas Product
11. BioStorage Technologies, Inc., Appoints Jeff Goddard to Global Head of Sales
Post Your Comments:
(Date:11/27/2015)... 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ... it has closed the sale of its global contrast ... NYSE Euronext) in a transaction valued at approximately $270 ... and a total of approximately 1,000 employees spread across ... St. Louis area. This entire workforce and ...
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is ... cancer biomarkers market with pharmaceutical companies and ... companion diagnostic tests. . ... Complete report on global cancer biomarkers ...
(Date:11/26/2015)... England , November 26, 2015 ... innovative medical device company specializing in imaging technologies, announced today ... European Commission as part of the Horizon 2020 European Union ... carry out a large-scale clinical trial in breast cancer. ... (Logo: , --> --> ...
(Date:11/25/2015)... ANNAPOLIS, Md. , Nov. 25, 2015  PharmAthene, ... of Directors has adopted a stockholder rights plan (Rights ... its net operating loss carryforwards (NOLs) under Section 382 ... --> --> PharmAthene,s use of its ... an "ownership change" as defined in Section 382 of ...
Breaking Biology Technology:
(Date:11/9/2015)... Calif. , Nov. 9, 2015  Synaptics Inc. ... interface solutions, today announced broader entry into the automotive ... solutions that match the pace of consumer electronics human ... biometric sensors are ideal for the automotive industry and ... Europe , ...
(Date:10/29/2015)... Oct. 29, 2015   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Association (MHTA) as one of only three finalists for ... – Small and Growing" category. The Tekne Awards honor ... shown superior technology innovation and leadership. ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):